Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease.

Publication

Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease.

Journal Paper/Review - Nov 6, 2023

Philippen Lennart, Schub Natalie, Günther Andreas, Cario Gunnar, Schrappe Martin, Repp Roland, Gramatzki Martin

Citation

Philippen L, Schub N, Günther A, Cario G, Schrappe M, Repp R, Gramatzki M. Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease. Bone Marrow Transplant 2023; 59:153-155.

Type

Journal Paper/Review (English)

Journal

Bone Marrow Transplant 2023; 59

Publication Date

Nov 6, 2023

Issn Electronic

1476-5365

Pages

153-155